In the case of EGFR-mutant NSCLC, for instance, molecular profiling to detect co-mutations such as TP53, RB1, and PIK3C, which are known to be associated with primary resistance to osimertinib [39], could help identify patients who may benefit from early treatment with anti-TROP-2 agents. This evidence concerns the gene TP53 and non-small cell lung carcinoma.